# US 2013/0220335 A1 · Methods and Devices for Conduit Occlusion

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0220335 A1
- Document ID: US20130220335A1
- Status: Published application
- Kind: A1
- Application number: 13/684,546
- Filed: 2012-11-25
- Published: 2013-08-29
- Earliest claimed: 2004-02-25
- Assignees: Femasys Inc.
- Inventors: Kathy Lee-Sepsick; Max S. Azevedo; Daniel S. Currie
- Web page: https://patentgrep.com/patent/US20130220335A1

## CPC

- A61F 6/225: {transcervical}
- A61B 17/12099: {characterised by the location of the occluder}
- A61B 17/12159: {Solid plugs; being solid before insertion}
- A61B 17/12186: {liquid materials adapted to be injected}
- A61B 17/1219: {expandable in contact with liquids}
- A61B 17/12195: {comprising a curable material}
- A61B 17/42: Gynaecological or obstetrical instruments or methods {(ligaturing clamps or clips for the umbilical cord A61B17/122; curettage A61B17/320708)}
- A61B 17/12022: {Occluding by internal devices, e.g. balloons or releasable wires (plugging an opening in the wall of an organ A61B17/0057; occluders for the cervical canal A61F6/146; vas deferens occluders A61F6/20)}
- A61B 17/22012: {in direct contact with, or very close to, the obstruction or concrement (for removing obstructions in blood vessels by laser A61B18/245)}
- A61B 17/320758: {with a rotating cutting instrument, e.g. motor driven (A61B17/320725, A61B17/32075 and A61B17/320783 take precedence; for removing intra-ocular material A61F9/00763; endoscopic rotatable cutting instruments A61B17/32002)}
- A61B 2017/22051: {with an inflatable part, e.g. balloon, for positioning, blocking, or immobilisation (A61B2017/22048, A61B2017/3486 take precedence)}
- A61B 2017/22084: {stone- or thrombus-dissolving}
- A61B 2017/4225: {Cervix uteri}
- A61B 2017/4233: {Operations on Fallopian tubes, e.g. sterilization (A61B2017/1125 takes precedence)}
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)

## Abstract

The present invention comprises systems, methods and devices for the delivery of compositions for occluding or of elements for opening conduits. The implantable occlusive material may be delivered pre-formed or in situ cured and, may be a resorbable or degradable material that supports tissue ingrowth or wound healing or a similar response that replaces the cured occlusive material leaving little or no original occlusive material in place. The delivery system is positioned to allow for placement of the occlusive material into the body conduit. Use of delivery systems, methods and devices for re-opening an occluded body conduit are also included.

## Claims

### Claim at position 1

-23. (canceled)

### Claim 24

A method for occluding one fallopian tube in a human or animal body, comprising,
(a) providing a delivery system that delivers an effective amount of an occlusive material composition, wherein the delivery system comprises a delivery device comprising an introducer shaft comprising an atraumatic tip and defining one opening spaced from the atraumatic tip for providing a catheter; one catheter, wherein the catheter comprises an end structure on a delivery end, and means for providing an occlusive material composition into and through the catheter; and an occlusive material composition;
(b) positioning the atraumatic tip of the introducer shaft at or near the fundus of a uterus;
(c) positioning the delivery end of the catheter at or near a uterine cornua such that the end structure is at or near a tubal ostium, wherein the end structure maintains the delivery end in the uterine cornua and aids in localized delivery of the occlusive material composition;
(d) delivering from the catheter an effective amount of the occlusive material composition at or near the ostia of the fallopian tubes; and
(e) occluding one fallopian tube by forming an occlusion with the occlusive material composition within the lumen of the fallopian tube.

### Claim 25 (depends on 24)

The method of claim 24, wherein the fallopian tube is fallopian tube of a human.

### Claim 26 (depends on 24)

The method of claim 24, wherein the occlusive material composition comprises a tissue adhesive.

### Claim 27 (depends on 24)

The method of claim 24, wherein the occlusive material composition is ultrasound visible.

### Claim 28 (depends on 27)

The method of claim 27, wherein the ultrasound visible material comprises microbubbles of air or gas or microparticles of a material that entrap air or gas.

### Claim 29 (depends on 26)

The method of claim 26, wherein the tissue adhesive is cyanoacrylate, polyacrylic acids, polyethylene glycols, modified polyethylene glycols, thrombin, collagen, collagen-based adhesives, fibrin, fibrin glue compositions, gelatin-resorcinol-formaldehyde-glutaraldehye (GRFG) glue, autologous blood in combination with collagen or thrombin, crosslinked albumin adhesives, modified glycosaminoglycans, poly(N-isopropylacrylamide)-based adhesives, alginates, or chitosan or gelatin, crosslinked with carbodiimide or genepin or combinations thereof.

### Claim 30 (depends on 24)

The method of claim 24, wherein the occlusive material composition cures, and the cured composition swells less than 20%.

### Claim 31 (depends on 24)

The method of claim 24, wherein the c occlusive material composition is about 20% to about 100% substantially resorbed or degraded in a range of about 30 to about 90 days.

### Claim 32 (depends on 24)

The method of claim 24, wherein the occlusion is maintained by tissue ingrowth or wound healing or similar type response.

### Claim 33 (depends on 24)

The method of claim 24, wherein the occlusive material composition further comprises polymers or particles.

### Claim 34 (depends on 33)

The method of claim 33, wherein the particles are nano- or micro-particles.

### Claim 35 (depends on 24)

The method of claim 24, wherein the occlusive material composition comprises polymers.

### Claim 36 (depends on 24)

The method of claim 24, wherein the occlusive material composition further comprises tissue scarring agents, fibrosis agents, wound healing promoting agents, fertilization inhibitors, contraceptive agents, tissue growth promoters, hormones, polymerization inhibitors, polymerization stabilizers, emulsifying agents, echogenic agents, contrast agents, viscosity-modifying materials, plasticizers, colorants or combinations thereof.

### Claim 37 (depends on 24)

The method of claim 24, wherein the occlusive material composition further comprises a curable carrier for the occlusive materials, a control release agent, tissue scarring agents, wound healing promoting agents, fibrosis agents, fertilization inhibitors, contraceptive agents, tissue growth promoters, hormones, polymerization inhibitors, polymerization stabilizers, emulsifying agents, echogenic agents, contrast agents, viscosity-modifying materials, plasticizers, colorants or combinations thereof.

### Claim 38

A method for contraception, comprising,
(a) providing a delivery system that delivers an effective amount of an occlusive material composition, wherein the delivery system comprises a delivery device comprising an introducer shaft comprising an atraumatic tip and defining one opening spaced from the atraumatic tip for providing a catheter; one catheter, wherein the catheter comprises an end structure on a delivery end; and means for providing an occlusive material composition into and through the catheter; and an occlusive material composition;
(b) positioning the atraumatic tip of the introducer shaft at or near the fundus of a uterus;
(c) positioning the delivery end of the catheter at or near a uterine cornua such that the end structure is at or near a tubal ostium, wherein the end structure maintains the delivery end in the uterine cornua and aids in localized delivery of the occlusive material composition;
d) delivering an effective amount of the occlusive material composition at or near the tubal ostium such that the occlusive material is provided to a portion of a lumen of a fallopian tube; and
(e) occluding the fallopian tube by forming an occlusion with the occlusive material composition within the lumen of the fallopian tube.

### Claim 39 (depends on 38)

The method of claim 38, wherein the fallopian tube is fallopian tube of a human.

### Claim 40 (depends on 38)

The method of claim 38, wherein the occlusive material composition comprises a tissue adhesive.

### Claim 41 (depends on 38)

The method of claim 38, wherein the occlusive material composition is ultrasound visible.

### Claim 42 (depends on 41)

The method of claim 41, wherein the ultrasound visible material comprises microbubbles of air or gas or microparticles of a material that entrap air or gas.

### Claim 43 (depends on 40)

The method of claim 40, wherein the tissue adhesive is cyanoacrylate, polyacrylic acids, polyethylene glycols, modified polyethylene glycols, thrombin, collagen, collagen-based adhesives, fibrin, fibrin glue compositions, gelatin-resorcinol-formaldehyde-glutaraldehye (GRFG) glue, autologous blood in combination with collagen or thrombin, crosslinked albumin adhesives, modified glycosaminoglycans, poly(N-isopropylacrylamide)-based adhesives, alginates, or chitosan or gelatin, crosslinked with carbodiimide or genepin or combinations thereof.
